4119 — SCI Pharmtech Income Statement
0.000.00%
- TWD8.54bn
- TWD8.84bn
- TWD1.52bn
- 67
- 33
- 35
- 41
Annual income statement for SCI Pharmtech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,689 | 864 | 900 | 1,204 | 1,524 |
Cost of Revenue | |||||
Gross Profit | 1,274 | 208 | 291 | 350 | 411 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 1,638 | 791 | 781 | 1,044 | 1,325 |
Operating Profit | 1,052 | 73.7 | 119 | 160 | 198 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 455 | 65.5 | 388 | 364 | 647 |
Provision for Income Taxes | |||||
Net Income After Taxes | 360 | 55.7 | 309 | 295 | 535 |
Net Income Before Extraordinary Items | |||||
Net Income | 360 | 55.7 | 309 | 295 | 535 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 360 | 55.7 | 309 | 295 | 535 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.26 | 0.508 | 2.82 | 2.69 | 4.46 |
Dividends per Share |